Abstract
Background: Rosuvastatin has been reported to be beneficial in the treatment of dyslipidemia. The Cmax and AUC0−t of rosuvastatin were reported to be ~2 to 4 times higher in Chinese subjects compared with white subjects after administration of a single 1-mg/kg dose.
Objectives: The aims of this study were to assess the pharmacokinetics and tolerability of multiple doses of rosuvastatin in healthy Chinese volunteers.
Methods: This open-label, randomized-sequence, 3-way crossover trial consisted of three 7-day treatment periods and two 10-day washout periods. Healthy volunteers were randomly allocated to 1 of 3 daily treatment regimens: rosuvastatin 5, 10, or 20 mg. To assess the pharmacokinetics and tolerability of rosuvastatin, blood samples were drawn before dosing (hour 0) on days 5, 6, and 7 and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, 72, and 96 hours after the final dose was administered on day 7. A validated HPLC-MS/MS method was used to determine rosuvastatin levels. A 2-compartment pharmacokinetic model was fitted to the plasma concentration-time profiles obtained for each volunteer. Adverse events (AEs) were monitored throughout the study via subject interview, vital signs, and blood sampling. Serious AEs were those requiring hospitalization, treatment discontinuation, or resulting in death.
Results: Twelve healthy Chinese volunteers (6 men: mean [SD] age, 21.8 [1.7] years; weight, 62.3 [5.8] kg; height, 174.3 [7.2] cm; 6 women: age, 20.8 [1.2] years; weight, 53.2 [4.7] kg; height, 161.3 [4.3] cm) participated in and completed the trial. The mean (SD) steady-state Cmax was significantly greater after ro-suvastatin administration in the 20-mg group compared with the 5-mg group (37.69 [29.83] vs 6.17 [6.03] ng/mL; P = 0.04). The t1/2 was significantly greater in the 20-mg group (15.51 [6.43] hours) compared with the 5-mg group (5.65 [5.08] hours; P = 0.001) and the 10-mg group (8.58 [5.17] hours; P = 0.002). The mean AUC0−t was significantly greater in the 20-mg group compared with the 5-mg group (349.16 [257.20] vs 40.63 [39.31] ng/mL/h; P = 0.02). All AEs were considered by the investigators to be mild in intensity, with the exception of 2 cases of abdominal discomfort (1 man and 1 woman, both in the 5-mg dose group). Two women in the 20-mg group experienced dizziness and cold sweats simultaneously. In the 10-mg group, 1 woman had abdominal discomfort and nausea and 1 woman had jaw pain. All reported AEs were considered possibly related to study drug administration.
Conclusions: In this small study in healthy Chinese volunteers, rosuvastatin systemic exposure appeared to be dose-proportional over the dosing range of 5 to 20 mg with multiple-dose administration. There was no accumulation of rosuvastatin in the body with the 5- and 10-mg doses. However, the results suggest that rosuva-statin might accumulate when the dose is increased to 20 mg. No serious AEs occurred in any of the 3 dosing groups.
Key words: rosuvastatin, pharmacokinetics, multiple doses, tolerability, Chinese
Full Text
The Full Text of this article is available as a PDF (198.7 KB).
References
- 1.Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atheroscler Suppl. 2002;2:33–36. doi: 10.1016/s1567-5688(01)00016-2. discussion. [DOI] [PubMed] [Google Scholar]; Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atheroscler Suppl. 2002;2:36–37. doi: 10.1016/s1567-5688(01)00016-2. [DOI] [PubMed] [Google Scholar]
- 2.Brown WV, Bays HE, Hassman DR, Rosuvastatin Study Group Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J. 2002;144:1036–1043. doi: 10.1067/mhj.2002.129312. [DOI] [PubMed] [Google Scholar]
- 3.Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs. 2002;62:2075–2085. doi: 10.2165/00003495-200262140-00008. [DOI] [PubMed] [Google Scholar]
- 4.Pirro M, Schillaci G, Mannarino MR. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2006;17:436–441. doi: 10.1016/j.numecd.2006.02.009. [DOI] [PubMed] [Google Scholar]
- 5.Kostapanos MS, Filippatos TD, Gazi I. Effect of rosuvastatin on low density lipoprotein (LDL) concentration and relative distribution in patients with primary dyslipidaemia. Atheroscler Suppl. 2006;3:499. [Google Scholar]
- 6.Martin PD, Dane AL, Nwose OM. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol. 2002;42:1116–1121. doi: 10.1177/009127002401382722. [DOI] [PubMed] [Google Scholar]
- 7.Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54:472–477. doi: 10.1046/j.1365-2125.2002.01688.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cooper KJ, Martin PD, Dane AL. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2002;58:527–531. doi: 10.1007/s00228-002-0508-8. [DOI] [PubMed] [Google Scholar]
- 9.Cooper KJ, Martin PD, Dane AL. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003;55:94–99. doi: 10.1046/j.1365-2125.2003.01720.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Li Y, Jiang X, Lan K. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: A randomized, open-label, three-way crossover study. Clin Ther. 2007;29:2194–2203. doi: 10.1016/j.clinthera.2007.10.005. [DOI] [PubMed] [Google Scholar]
- 11.Lee E, Ryan S, Birmingham B. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–341. doi: 10.1016/j.clpt.2005.06.013. [DOI] [PubMed] [Google Scholar]
- 12.Hong Z, Yuqing X. Pharmacokinetics of rosuvastatin calcium tablets in Chinese healthy volunteers after a single oral dose administration. Chin J Clin Pharmacol. 2007;23:268–271. [Google Scholar]
- 13.Aidong Wen, Linlin Bi, Xiaoxing Luo. Determination of rosuvastatin in human plasma by LC/MS/MS and study of pharmacokinetics. Pham J Chin PLA. 2007;23:110–113. [Google Scholar]
- 14.Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25:2215–2224. doi: 10.1016/s0149-2918(03)80214-x. [DOI] [PubMed] [Google Scholar]
- 15.Lan K, Jiang X, Li Y. Quantitative determination of rosuvastatin in human plasma by ion pair liquid-liquid extraction using liquid chromatography with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2007;44:540–546. doi: 10.1016/j.jpba.2006.12.022. [DOI] [PubMed] [Google Scholar]